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Abstract
Diabetic retinopathy (DR) is a common cause of vision loss and blindness. Healthy CD34+
stem cells are capable of homing to vascular lesions and facilitating vascular repair.
However, many diabetic patients have dysfunctional CD34+ stem cells with no reparative
potential. CD34+ dysfunction is corrected by transiently inhibiting endogenous
transforming growth factor-β1 (TGF-β1) within the patient’s own dysfunctional CD34+
stem cells using phosphorodiamidate morpholino oligomers (PMOs). Antisense TGF-β1-
treated dysfunctional CD34+ stem cells are now functional, no longer require growth
factor stimulation to evade apoptosis, and are stable at 37C ex vivo for >5 days. We
identified three markers of restored stem cell function: (1) upregulation of CXCR4 expres-
sion necessary for stem cell homing and adhesion, (2) SDF-1-mediated nitric oxide (NO)
production required for cell mobility, and (3) restoration of the ability of CD34+ cells to
migrate and repair vascular lesions. The antisense targets autocrine TGF-β expression,
whereas neutralizing antibodies do not. The PMO antisense triggers a cascade of hemato-
poietic proliferation and differentiation that paracrine TGF-β cannot alter. We describe
optimal PMO manipulation of CD34+ stem cells ex vivo for transplantation, screening
multiple gene targets leading to the identification of TGF-β1, and a lead TGF-β1 inhibitor
evaluated in clinical studies.
Keywords: diabetic retinopathy, stem cell therapy, transforming growth factor-β1
(TGF-β1), phosphorodiamidate morpholino oligomers (PMOs), transient antisense
1. Introduction
Hematopoietic stem cells (HSCs) are capable of self-replication and clonal expansion generat-
ing differentiated progenitors, which give rise to all blood cell lineages [1]. These cells
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co-express transforming growth factor-β (TGF-β) type I and type II receptors and one or more of
the three isoforms of the TGF-β ligand as a latent complex [2]. The three TGF-β ligands qualita-
tively and quantitatively differ in the responses they elicit with TGF-β1, a multifunctional
regulator of hematopoietic progenitors in vivo and in vitro, depending on cell differentiation,
growth factors, ligand concentration, and cell–cell contacts [3]. Autocrine signaling by TGF-β1
plays a critical role in lineage-specific reconstitution [4] and enables non-canonical signaling
involving mTOR, Ras, MAPK, PI3K, AKT, RhoA, and JNK [5]. TGF-β is an important part of
the stromal microenvironment that regulates several niche cells, which in turn regulate HSC.
Selective manipulation of endogenous TGF-β1 in HSC represents a therapeutic approach to
transplantation to maintain, enhance, and restore tissue viability and organ function.
Transient inhibition of TGF-β1 in HSC accelerates the engraftment of long-term repopulating
HSC (LTR-HSC), permits successful transplantation with as few as 60 LTR-HSCs to rescue
mice from lethal irradiation, and promotes the survival of LTR-HSC in the absence of growth
factors [6]. This permits LTR-HSC transplant without cell expansion ex vivo prior to trans-
plant. TGF-β1 regulates LTR-HSC entry into the cell cycle at G0 [7]. Conditional knock-out of
the TGF-β1 type II receptor in adult mice has increased stem cell cycling and reduced trans-
plantation ability [8]; likewise, the inhibition of TGF-β in normal HSC with neutralizing
antibodies releases cells into the cell cycle [9]. Inhibiting SMAD 4 signaling, key to TGF-β
signaling, decreased HSC self-renewal in vivo [10]. The rapid generation of donor neutrophils
that are the last cells to regenerate in bone marrow transplantation (BMT) is observed in
transplanted mice after LTR-HSCs were treated with an antisense TGF-β1 PMO [6].
Phosphorodiamidate morpholino oligomers (PMOs) resist degradation [11], enhance specific-
ity through a no-pucker six-membered morpholine ring in place of the five-membered ribose
or deoxyribose [12], and are net charge neutral with one non-bridging oxygen substituted with
a dimethylamine residue [13]. PMOs binds to the target RNA, forming a PMO:RNA heterodu-
plex that can inhibit translation [14] or pre-mRNA splicing [15]. The cellular internalization of
PMOs in different cell types is mixed and not robust unless entry is assisted by cell uptake
technologies [16]. Given the impressive safety profile for unmodified PMO [17–19], conjuga-
tion with delivery enhancements adds risk. An unmodified PMO represents the most specific
and least risk to the modulation of gene expression in HSC.
Antisense TGF-β will reverse HSC growth arrest induced by TGF-β ligand, informing the
reversibility of the ligand [20]. The antisense approach gains access to autocrine RNA expres-
sion over neutralizing antibodies, which targets protein. Transient antisense inhibition of
autocrine TGF-β1 in HSC triggers a cascade of hematopoietic proliferation and differentiation
that paracrine TGF-β cannot alter [21]. We report the kinetics of HSC internalization and efflux
of PMO essential to transient inhibition of TGF-β1.
2. Feasibility: PMO entry into CD34+ stem cells
Evidence for receptor-mediated internalization of DNA came from studies with leukocytes
over 30 years ago [22]. Uptake involves endocytosis based on chloroquine, a lysosomotropism
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agent, enhanced intracellular fluorescence, sodium azide inhibited internalization, and a punc-
tate pattern observed in the cytoplasm [23]. Scavenger receptors on rat liver endothelial cells
participate in uptake and play a prominent role in plasma clearance [24]. Many oligonucleo-
tide uptake pathways have been described, but the adaptor protein AP2 M1 is involved in
phosphorothioate oligonucleotide (PSO) uptake. siRNA targeting clathrin and caveolin had no
effect on antisense activity but did decrease the uptake of fluorescently labeled oligonucleo-
tides, highlighting multiple subcellular compartments that accumulate oligonucleotides but
not all are associated with antisense activity. Abasic oligomers, backbone and sugar without
nucleobase oligomers, were not transported into cells by the AP2 M1 pathway [25], pointing to
the nucleobase as a recognition site for uptake. The neutral charge of PMO compounds sets
them apart from ionic forms like PSO.
We explored techniques to deliver PMO into cells in culture to improve bioavailability and
efficacy including scrape loading [26], syringe loading [27], microinjection [28], osmotic load-
ing [29], and complexation with cationic lipids [30]. These techniques suffer from limited
efficiency and poor reproducibility and often leave residual biologically active carrier mole-
cules in the culture media. We then explored a variety of cationic peptides conjugated to the
PMO for an enhanced delivery including HIV-TAT [31] and a broad spectrum of arginine-rich
peptides [32–34]. At present, the optimal delivery peptide is still composed of multiple argi-
nines [35]. A concern for loading arginine into a stem cell was the role arginine plays in
generating NO, a complication in interpreting observations of CD34+ activation. Thus, we
examined unassisted entry in stem cells.
Earlier studies evaluating unassisted PMO entry into cultured cells revealed that primary cell
cultures are more efficient in uptake than established cell lines. Uptake is independent of PMO
sequence or the position of FITC conjugation (50 vs. 30 ends are equivalent) (Figure 1A) but
dependent on concentration (Figure 1B), time, and temperature. There is a direct relationship
between fluorescence intensity of CD34+ cells and PMO concentration. Localization to both
cytoplasmic and nuclear compartments is observed, so that both pre-mRNA and mRNA targets
are feasible. Uptake into hematopoietic lineages reveals that monocytes and dendritic cell uptake
are efficient, while entry into CD8+ T-cells, CD4+ T-cells, and B-cells is minimal [36]. Viral
infection activates some T-cell populations, resulting in permissive PMO uptake [37]. Current
understanding of mechanisms involved in activation associated with PMO uptake is limited.
The first evidence of unassisted PMO entry into CD34+ cells came from microscopic observa-
tion of cells in which the visible uptake of FITC-PMO came within 15 min. Stem cells are
unique in permissive unassisted PMO uptake. The maximal saturation of PMO uptake into
HSC occurs within 2 h (Figure 2). Optimal uptake in terms of activation of HSC occurs after
16 h of FITC-PMO incubation. Stem cell positivity after 16 h was observed at 37C with
70  12% FITC-positive CD34+ cells (n = 6), room temperature incubation led to 56  8%
positive cells (n = 5), and 4C incubation led to 30  19% positive cells (n = 6). The percent
FITC-PMO-positive CD34+ cells were mirrored by cellular fluorescence defined by mean
channel fluorescence with 112  47 at 37C, 56  22 at room temperature, and 31  24 at 4C
incubation. Negative controls included CD34+ cells incubated with no FITC-PMO at 4C, RT,
and 37C (n = 6) for each group, and no FITC-PMO-positive cells were observed.
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Figure 1. Concentration-dependent uptake of FITC-PMO into CD34+ human stem cells. A. Percent-positive CD34+
HSC on the ordinate and PMO concentration on the abscissa. B. Mean channel fluorescence of CD34+ HSC on the ordinate
and PMO concentration on the abscissa. The uptake of PMOs is not sequence specific: 20-mer PMOs have similar entry
kinetics, and percent-positive CD34+ cells are directly proportional to the PMO concentration in the medium. CD34+ cells
were isolated from the blood of healthy subjects by pre-enriching the CD34+ by a lineage negative selection followed by
FACS sorting of CD34+ CD45+ cells.
Figure 2. Time-dependent uptake of FITC-PMO into CD34+ human stem cells. After 3 h at 37C at 150 μg/mL 144-F
(a FITC-control PMO), >95% of CD34+ cells became FITC-labeled. At 16 h in culture, the degree of FITC-144-F PMO was
the same as the 3-h point. CD34+ cells were isolated and FACS sorted from the blood of healthy subjects as described in
Figure 1.
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PMO uptake was found to be time and dose dependent. Uptake reached 100% FITC-PMO-
positive CD34+ cells between 1 and 6 h of incubation at 37C. Uptake determined as percent-
positive CD34+ cells measured over time were linear (r2 0.94–0.94) (Table 1). Comparison of
CD34+ cells recovered from diabetic individuals to non-diabetic individuals reveals that uptake
is three to five times more rapid in non-diabetic CD34+ cells compared to those from diabetic
individuals (Table 1, Figure 3). No loss in cell viability has been observed in protocols involv-
ing a 6-h incubation sufficient for 100% PMO-positive cells. Preliminary data suggest that
treated stem cells will carry less than 5 μg PMO into the eye as a result of a combination of
Treatment group Rate percent pos./H (r2)c Ratios (expected) Time to 100% pos. Saturation ratio
Norma 40 μg (N = 2) 17.6  1.1 (0.95) 3.3 (N/D 40) 6 h 3.0 (D/N 40)
Diabb 40 μg (N = 1) 5.3  5.2 (0.95) 3.4 (D 160/40) [4] 18 h 3.6 (D 40/160) [4]
Norm 160 μg (N = 2) 98.0  7.3 (0.94) 5.6 (N 160/40) [4] 1 h 6.0 (N 40/160) [4]
Diab 160 μg (N = 1) 18.1  8.2 (0.94) 5.4 (N/D 160) 5 h 5.0 (D/N 160)
aCD34+ cells recovered from normal donors.
bCD34+ cells recovered from diabetic donors.
cCorrelation coefficient from linear regression analysis.
Table 1. PMO uptake kinetics in CD34+ cells.
Figure 3. The percent of blood-derived CD34+ cell taking up FITC-PMO. A. Percent-positive (black bar) and mean
channel fluorescence (gray bar) CD34+ cells from healthy donors. B. Percent-positive (black bar) and mean channel
fluorescence (gray bar) CD34+ cells from diabetic subjects. Uptake is not different in healthy and diabetic subjects, but
the rates of maximum saturation of FITC-PMO (measure by MEAN CHANNEL FLUORECENCE) are delayed in diabetic
CD34+ cells relative to non-diabetic cells. CD34+ cells were pre-enriched and FACS sorted as described above.
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efflux out of the cell, and tissue half-life will quickly lead to undetectable PMO and a transient
inhibition of TGF-β in the stem cells. The overall exposure of PMO will be below 100,000 times
the reported no observed adverse effect level (NOAEL) for a similar PMO in GLP toxicology
studies [38, 39]. The use of PMO-treated CD34+ stem cells to treat patients with diabetic
retinopathy is expected to be safe and feasible.
3. Optimal TGF-β PMO inhibitors in human Lin-CD34+ CD45+ HSC
TGF-β is a family of multifunctional peptide cytokines with the capacity to regulate prolifera-
tion, differentiation, adhesion, migration, and other functions in many cell types. TGF-β
receptors are found on most cells, and their signal transduction positively and negatively
regulates many other growth factors. Secreted TGF-β is cleaved into a latency-associated
peptide (LAP) and a mature TGF-β1 protein. TGF-β is latent in the form of a TGF-β1
homodimer, a LAP homodimer, and a latent TGF-β1-binding protein (LTBP). However,
TGF-β1 homodimer can be active, and the mature protein may also form heterodimers with
other TGF-β family members.
The HSC is pluripotent immature cell that can generate daughter cells committed to all nine
types of mature blood cells, including trillions of white blood cells, red blood cells, and
platelets. HSCs are found in the bone marrow and also circulate in the peripheral blood. HSC
possesses two key properties: (1) the ability to self-renew (generating HSC replicates) and (2)
the ability to generate daughter cells that differentiate into fully functional blood cells (namely,
asymmetrical HSC division in which one daughter cell remains a HSC and the other daughter
cells are destined to mature).
When the most primitive HSCs self-replicate, they produce daughter cells with a long (possi-
bly unlimited) clonal life span. When HSC replication leads to differentiation divisions, they
lose their multi-lineage potential and the corresponding lineage commitment accompanied by
a progressive reduction in clonal life span. Previous studies have shown that ex vivo prolifera-
tion of HSC favors differentiation divisions at the expense of self-replication, resulting in a
complete loss of HSC.
4. TGF-β is an optimal stem cell target for CD34+ stem cells
An inhibitor of c-myc was identified based on antiproliferative effects in differentiated cells
that block translation as well as create a dominant-negative variant of c-myc [40]. This inhibi-
tor was effective in preventing coronary restenosis [41], preventing cyst growth in kidneys of
polycystic kidney disease models [42], and reducing tumor growth [43]. We investigated the c-
myc inhibitor in c-kit+/sca-1+ cells incubated with IL-3, IL-6, and SCF to drive cell proliferation
of the stem cells. Incubation of these cells with saline was associated with a cell doubling half-
life of 2.66 days, a scrambled sequence PMO (5’-GCTATTACCTTAACCCAG-30) had a dou-
bling half-life of 2.554 days, and the c-myc inhibitor (5’-ACGTTGAGGGGCATCGTCGC-30)
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had a doubling half-life of 2.53 days. Unlike differentiated cells, the stem cells show no
difference in cell proliferation when c-myc was inhibited. While inhibiting, c-myc did not
influence proliferation rate; however, it did enhance stem cell differentiation as high prolifera-
tion potential (HPP) colony forming counts (CFC) rose from 3.8 HPP CFC in controls to 8.0
HPP-CFC in c-myc-inhibited cultures. This surprising observation suggested that c-myc inhibi-
tion stimulates stem cell differentiation and regulates self-renewal inspired studies to look at
upstream signaling pathways in these stem cells. We studied the inhibition of ecotropic virus
insertion-1 (EVI-1), which inserts in the DNA of murine stem cells and c-Kit, a stem cell marker
along with c-myc and found that PMO-antisense treatment in vitro decreased LTR-HSC
repopulating ability (Figure 4). Furthermore, the intra-peritoneal administration of PMO anti-
c-myc reduces HSC-repopulating ability in vivo (Figure 5). These results represent an excellent
functional control for PMO-TGF-β1 since these PMO antisense treatments do not promote
HSC engraftment while PMO-TGF-β1 does.
ID11, a neutralizing monoclonal antibody to three isoforms of TGF- β (TGF- β1, 2, 3), added to
stem cell cultures can replace growth factors and prevent apoptosis in mouse HSC [7]. Adding
100 c-kit+/sca-1+ cells to 96-well plates with no IL-3, IL-6, or SCF led to no cells observed after
5 days in culture. Adding ID11 to those cultures led to 37  7 cells, confirming that the
antibody could replace growth factors. Further, the addition of the PMO targeting c-myc led
to 10  3 cells at 5 days in culture, leading us to conclude that c-myc expression is required for
the loss of TGF-β phenotype. It became apparent that ID11 effectively blocks extracellular
TGF-β, but a PMO (5’-GCA CTG CCG AGA GCG CGA ACA-30) inhibitor of TGF-β translation
could have the advantage of blocking autocrine signaling. Inhibiting TGF-β with either anti-
body or antisense PMO enhances HPP-CFC from progenitor cells [7, 20, 21] and can enhance
hematopoietic reconstitution following bone marrow transplantation [6, 44, 45]. Importantly,
Figure 4. PMO targeting of c-myc, c-kit, and EVI-1 in ex vivo cultures of highly purified murine LTR-HSC. LTR-HSCs
were isolated as previously described, then 25 cells per well were incubated for 5 days with PMO and hematopoietic
growth factors followed by intravenous transplant into lethally (950 rads) irradiated mice. CD45.2 congenic LTR-HSCs
were transplanted into CD45.1 recipients, so that donor LTR-HSC could be detected by monoclonal antibodies. Signifi-
cantly fewer (p < 0.05) LTR-HSCs were observed in cultures treated with c-kit, EVI-1, and c-myc PMO compared to control,
c-myc scramble, and c-kit scramble PMO after 3 months post-transplant.
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Figure 5. In vivo activity of PMO targeting c-myc in short-term and long-term hematopoietic stem cells. Mice were
treated with c-myc-PMO in vivo (intraperitoneal injection) for 2 or 11 days. At each time point, mice were sacrificed, and
the femoral marrow was assayed for HSC levels using a murine transplantation model. Significant reductions in
repopulating HSC (p < 0.05) were observed in mice treated with c-myc PMO compared to normal bone marrow.
Figure 6. Targeting stem cell pathways. Studies were conducted targeting c-myc, SMAD4, EVI-1, c-kit, TGF-βRI, TGF-
βRII, and TGF-β1 with PMOs designed to inhibit expression in HSC. Regulation of transcription factors by TGF-β1 is
linked to stem cell homing through CXCR4 interaction with SDF-1 and release of nitric oxide and elevated migration. The
MAP kinase pathway signaling reveals the potential mechanism for the prevention of apoptosis with TGF-β1 inhibition.
The upstream regulation of c-myc and p53 by TGF-β1 inhibition allows stem cells to proliferate. Inhibition of TGF-β1 is
the optimal target resulting in stem cell proliferation, homing, and migration of all favorable properties for autologous
transplantation.
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the transplantation of Tfgβ1/ bone marrow into lethally radiated TGF-β1+/+ recipients recon-
stitutes all hematopoietic lineages [46]. Taken together, these studies encouraged further exam-
ination of the TGF-β1-signaling pathway.
We investigated PMO inhibitors of TGF-β receptor I (5’CAT GGT CCC TGC AGA GAG GA-30)
and TGF-β receptor II (5’-GAC CCA TGG CAG CCC CCG TCG-30) to reveal the same pheno-
type to the TGF-β1 ligand inhibitor. Subsequent studies targeting SMAD 4 (50-AAT CATACT
CAT CCT TCA CCA TCA T-30) also led to the TGF-β-inhibited phenotype in CD34+ cells,
confirming that the signal transduction pathway is responsible for the phenotype, while
blocking other pathways did not (Figure 6). We focused on the TGF-β1 ligand due to the short
half-life, enabling rapid onset and transient inhibition properties of the treatment.
5. The optimal TGF-β1 inhibitor
We investigated the use of an antisense PMO targeting the AUG translation start site for
efficacy in inhibiting TGF-β1 expression by hybrid arrest of translation. One possible outcome
of a PMO at AUG1 will be for translation slippage to a translation initiation start site at amino
acid 38, AUG38 (Figure 7). The resulting protein will not have the signal peptide, leading to
the loss of appropriate subcellular localization, altered autocrine regulation, and possibly a
protein with a shorter half-life. The diminished protein product fails to provide a negative
feedback to the promoter, so enhanced transcription is expected. To test this hypothesis, we
evaluated six oligomers targeting translation and two scrambled control sequences (Table 2).
The compounds were evaluated in an in vitro translation assay using rabbit reticulocyte lysate
and a luciferase fusion transcript with TGF-β1 mRNA. Each of the antisense PMOs effectively
inhibited translation, and the scrambled control oligomers did not inhibit, confirming PMO
sequence specificity. The TGF-β1 PMO included 13 guanines (G) in the 20-mer and presented
water solubility limitations and reduced synthetic yield concerns. Replacing guanine with
inosine improved both water solubility and synthetic yield. However, inosine pairing with
cytosine involves two hydrogen bonds in contrast to the three hydrogen bonds between
guanine and cytosine. The hypothesis is that the more inosine replacement of guanine in the
oligomer will result in a lower binding energy between PMO and target RNA and subsequent
Figure 7. Optimal antisense strategy. Multiple PMOs were developed to inhibit translation initiation at the AUG site as
well as targeting each exon at both splice donor and splice acceptor sites (black bars). Skipping exons 2, 3, 5, and 6 results
in out-of-frame reading, and a nonsense-mediated decay (NMD) of the transcript is expected (X circles).
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diminished inhibition of translation. By contrast, the PMO with three inosines, TGF-β1 3-I
(1067), inhibited translation more effectively than PMOs with all guanine or PMOs in which
one or two guanines were replaced by inosine (data not shown).
TGF-β1 has seven exons transcribed into eight variant mRNAs, five alternately spliced variants
and three unspliced forms (Figure 7). A small signal peptide (29 amino acids) is encoded in
exon 1; the precursor LAP is encoded in exons 1 through 5; the active TGF-β1 is encoded in
exons 6 and 7. The LTBP is encoded by a separate gene and binds directly to the LAP in the
latent TGF-β complex prior to secretion. The amino terminus of LTBP binds to the extracellular
matrix followed by proteolytic cleavage by a serine protease, plasmin, releasing the latent
complex. A urokinase plasminogen activator (uPA) protease cuts the 391-amino acid TGF-β1
propeptide liberating the active 112 amino acid TGF-β1, which forms a homodimer ligand for
the TGF-β receptors [47].
The TGF-β N terminal domain is present in a variety of proteins, which include TGF-β,
decapentaplegic peptides, and bone morphogenetic proteins. The N-terminal domain
expressed on the decapentaplegic protein acts as an extracellular morphogen guiding: (1) the
proper development of the embryonic dorsal hypoderm, (2) viability of larvae, and (3) cell
viability of the epithelial cells in the imaginal disks. When the N terminal domain is expressed
on the bone morphogenetic protein (BMP), it induces cartilage and bone formation, possibly
for epithelial osteogenesis. TGF-β1 is a protein composed of 112 amino acid residues liberated
by proteolytic cleavage from the C-terminal of a precursor protein. A number of proteins are
related to TGF-β1. The TGF-beta family is only active as homo- or heterodimers, the two chains
being linked by a disulphide bond. X-ray studies of TGF-β2 reveal that all the other cysteines
are involved in intrachain disulphide bonds. The four disulphide bonds in TGF-β and in the
inhibin beta chains distinguish function from the other members of this family that lack the
first bond. Concern has been noted as TGF-β not only exerts tumor-suppressive effects but also
modulates cell invasion and immune regulation such that dysregulation of the TGF-β signal-
ing pathway can result in tumor development.
Name Sequence 50 ! 30 Mol Wt.
GT Control CCTCCTACCTCAGTTACAATTTATA —
144 Control AGTCTCGACTTGCTACCTCA 7020
TGF-β1 GT GCACTGCCGAGAGCGCGAACA 7642
TGF-β1 GAGGGCGGCATGGGGGAGGC 7175
TGF-β1 1-I* GAGGGCGGCATGG I GGAGGC 7160
TGF-β1 3-I (1067) GAGGGCGGCATG III GAGGC 7130
TGF-β1 2-I GAG I GCGGCATGG I GGAGGC 7145
TGF-β1 4-I GAG I GCGGCATG III GAGGC 7115
*I refers to inosine, a strategy to limit “purine clash.”
Table 2. Oligomer sequences employed to inhibit TGF-β1 translation.
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In order to demonstrate PMO inhibition, THP-1 cells, which are human monocytes that
express TGF-β, were studied. THP-1 grows equally well in RPMI supplemented with 10% fetal
bovine serum and serum-free media. When grown in serum-free media, TGF-β is not secreted
into the media (ELISA = 0 pg./mL). Media supplemented with 50 ng/mL PMA lead to TGF-β
secretion (ELISA = 92 pg./mL). The addition of 10 μM atorvastatin (Lipitor) enhances TGF-β
secretion by fivefold (ELISA >500 pg./mL) following 72 h of incubation.
The evaluation of mRNA from splice altering PMOs is shown (Table 3). The control fragment
appears at the correct size. Cells treated with PMOs targeting SD Ex2, SD Ex4, and AUG show
no variation in transcript size and thus no evidence of exon skipping. The AUG signal appears
to be enhanced relative to the untreated control, possibly indicating a rebound induction of
transcription. This may be anticipated as the translation start site inhibitor will lead to sup-
pression of the propeptide including LAP, which may lead to loss of the negative feedback
mechanism for TGF-β1 transcription. Cells treated with PMOs targeting SD Ex5 and SD Ex6
reveal smaller transcripts in addition to faint bands at the correct size. The SD Ex5 smaller
transcript is consistent in size with the loss of exon 4 (74 bp), which would leave the mature
mRNA in frame. Those transcripts skipping exon 5 would be smaller yet (148 bp) and are
expected to be degraded by a nonsense-mediated decay (NMD), so that the product would not
be observed. The SD Ex6 smaller fragment is approximately 800 bp in size, which is 300 bp
smaller than the expected full-length transcript and consistent with loss of both exons 5
(148 bp) and 6 (156 bp), which would be 304 bp smaller than the full-length transcript.
Treatment
(5 μM 96 h)
Hu TGF-β1 protein
(pg/mL)
Mu TGF-β1 protein
(pg/mL) 5 μM 65 h
Cell viability
(% control)
No PMO 520  2 — 100
Scr Ctr 502  15 1700  10 88
SD Ex1* 385  7 — —
SA Ex2 387  5 — —
SD Ex2 BLD 1320  30 93
SA Ex3 594  21 — —
SD Ex3 222  3 — —
SA Ex4 465  12 — —
SD Ex4 23  2 520  20 66
SA Ex5 — —
SD Ex5 BLD 120  10 79
SA Ex6 404  18 — —
SD Ex6 BLD 330  10 79
SA Ex7 101  1 — 91
*SD refers to the splice donor site of the exon (Ex) and SA refers to the splice acceptor site.
Table 3. Exon skipping in THP-1 cells stimulated to secrete TGF-β1.
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Skipping exon 6 alone or exon 5 alone would be degraded by NMD, and those transcripts
would not be observed. Skipping exons 5 and 6 will also remain in frame.
The exercise to identify an optimal inhibitor of TGF-β1 involved screening multiple gene
targets and dozens of PMO inhibitors. Qualitative differences between splice-altering strate-
gies and translation inhibitors involve the preservation of feedback inhibition of the promoter.
Translation inhibitors and splice-altering targets that induce a nonsense-mediated decay
(NMD) prevent the synthesis of the negative feedback, resulting in compensatory transcription
followed by rebound translation of TGF-β1. By contrast, skipping of exons 5 and 6 leads to
translation products with altered function but includes the LAP portion of the translated
product, resulting in a prolonged inhibition of TGF-β1. Transient inhibition of TGF-β1 is
desired [48], so the optimal approach favors the AUG and NMD PMO over exon skipping
and ligand-neutralizing antibodies. Translation inhibition is preferred over NMD because
NMD responses may be less reliable.
6. Stem cell therapy for diabetic retinopathy
The Centers for Disease Control and Prevention report that 4.2 million (28.5%) of US diabetics
aged ≥40 years have diabetic retinopathy (DR) or damage to the small blood vessels in the
retina that may result in loss of vision [49]. The direct costs for DR in the US were over $4.5
billion, and the indirect economic impact was an additional $5 billion. Retinopathy occurs in
almost all patients with type 1 diabetes and 75% of patients with type 2 diabetes within
15 years of the manifestation of diabetes [50]. Over 12,000 diabetic patients become blind each
year due to ocular complications [51]. Current therapy addresses the end stages of DR includ-
ing laser photocoagulation, intravitreal antivascular endothelial growth factor (VEGF) agents
such as Bevacizumab and Aflibercept, intravitreal corticosteroids such as Triamcinolone, and
vitreoretinal surgery. CD34+ stem cells from diabetic patients cannot generate endothelial cells
to repair the vasculature, instead generating more inflammatory monocytes [52]. The CD34+
stem cell therapy described here exploits the ability of these cells to differentiate into a wide
variety of cell types to stimulate both vascular and neural regeneration to treat early stages of DR.
CD34+ cells are capable of homing to vascular lesions in the eye, mediating vascular repair
[53]. The use of autologous CD34+ cells eliminates the significant complication of transplant
rejection. However, diabetic CD34+ cells are dysfunctional, contributing to the diabetic com-
plication of DR [54]. While CD34+ cells from healthy subjects could repair retinal capillaries in
streptozotocin-induced diabetic mice, spontaneously diabetic obese BBZDR/Wor rats and neo-
natal mouse oxygen-induced retinopathy animal models CD34+ cells from diabetic mice could
not [55]. The approach described here restores function to dysfunctional diabetic CD34+ cells.
TGF-β1 is overexpressed and may cause dysfunction in diabetic CD34+ cells, and correction of
this overexpression can restore the regenerative ability of those cells in diabetics. TGF-β1 is the
major regulator of the balance between CD34+ proliferation, differentiation, and quiescence.
Transient inhibition of TGF-β1 with an optimal PMO (1) activates human CD34+ proliferation,
whereas ID11 antibody does not, (2) enhances CXCR4 cell surface expression and effective stem
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cell homing to SDF-1 ligand, (3) increases nitric oxide (NO) release, stimulating stem cell migra-
tion, and (4) increases vascular repair by the activated diabetic CD34+ cells. The transient TGF-β1
inhibition approach holds potential to impact other diabetic microvascular complications and
improve current bone marrow transplantation processes used in the treatment of blood cancers.
The transient inhibition of TGF-β1 in autologous diabetic CD34+ cells with an antisense PMO
ex vivo represents a feasible approach that poses minimal potential for adverse events and has
potential benefit to the patient with diabetic retinopathy. Challenges remain in development
such as the selection of animal models that adequately predict the human response to treat-
ment. Numerous features including the genetic basis of the retinal disease, anatomical differ-
ences in the eye, and the genesis of retinal damage limit the utility of animal models.
Substantial differences in diabetic subpopulations, the presence of comorbidities, patient age,
and diabetes severity will influence the success of our proposed therapy. A detailed under-
standing of the natural history of diabetic retinopathy deserves in-depth investigation, so that
patient enrollment can be refined, and clinical trials will examine optimal patient populations
and appropriate stage of disease. Current efforts are ongoing to address these limitations as
our protocol advances to the clinic.
7. Conclusions
Damaged retinal vessels are repaired by HSC in individuals throughout their life. Diabetic
HSC function is impaired, leading to the development of numerous clinically important con-
ditions including diabetic retinopathy. Selective ex vivo manipulation of TGF-β1 in diabetic
HSC represents a therapeutic approach to maintain, enhance, and restore vascular viability in
the retina. The PMO offers transcript selective binding and transient interference with transla-
tion of TGF-β1. The PMO offers a feasible technology in which they enter HSC, can inhibit
autocrine TGF-β1 signaling in HSC, and have an excellent safety profile. We presented the
process of selecting TGF-β1 as an optimal transcript and the optimal PMO sequence targeting
TGF-β1 mRNA. Our studies identified a transient interference with the translation of TGF-β1
in diabetic CD34+ HSC with an antisense PMO that will (1) upregulate the expression of
CXCR4, enabling stem cell homing and adhesion to sites of vascular injury in the retina, (2)
stimulation of nitric oxide production, enabling stem cell mobility, and (3) the release of cell
cycle checkpoints, enabling stem cell proliferation and differentiation required for the repair of
vascular lesions. The manipulated stem cell treatment strategy is making the transition from
discovery to preparation for clinical evaluation.
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